Biomarin Pharmaceutical Inc at Jefferies Healthcare Conference (Virtual) Transcript
Hi, everyone. This is Eun Yang, a biotech analyst with Jefferies. Welcome to Jefferies Virtual Healthcare Conference. It is my pleasure to host a fireside chat with the BioMarin management: J.J. Bienaimé, Chairman and CEO; Hank Fuchs, President of Worldwide R&D; and Brian Mueller, acting CFO.
Before we start the Q&A, J.J. will give us a brief opening remarks. J.J.?
©,-&
Thank you, Eun. So we appreciate the opportunity to participate in your virtual healthcare conference today. As you know, this past Sunday, we shared highlights from 4 years of clinical data with ROCTAVIANÂ gene therapy for the treatment of severe hemophilia A. We are very pleased that at 4 years after treatment, patients on our study remained off prophylactic therapy and have experienced less than 1 bleed per year on a cumulative basis over the 4 years of the study.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
